Table 1.
Participant Characteristicsa
| Characteristic | CMB(+) (n = 21) | CMB(−) (n = 34) | P Valueb |
|---|---|---|---|
| Female sex, No. (%) | 7 (33) | 15 (44) | .43c |
| PiB(+), No. (%)d | 13 (65) | 26 (79) | .30c |
| APOE*4 carrier, No. (%)e | 3 (15) | 4 (13) | .83c |
| Age, y | 87.6 (2.8) | 86.2 (2.5) | .06f |
| Cortical PiB SUVRd | 1.87 (0.55) | 1.81 (0.41) | .60f |
| SVBI | 1.81 (1.40) | 1.59 (1.31) | .62f |
| CVBI | 3.90 (2.55) | 2.74 (1.64) | .06f |
| Education, y | 16.42 (2.13) | 15.14 (2.86) | .06c |
| CDR0.5 global score, No. (%)g | 10 (48) | 3 (9) | .007f |
| Mini-Mental State Examination | 28.24 (1.14) | 28.62 (1.67) | .32c |
| Estimated verbal IQ | 113.59 (8.78) | 111.22 (8.92) | .33c |
| Memory | |||
| CVLT | |||
| Learning trials, range 0-60 | 50.20 (10.34) | 47.09 (10.29) | .28c |
| Delayed recall, range 0-16 | 10.19 (2.40) | 9.32 (3.24) | .26c |
| R-O figure delayed recall, range 0-24 | 16.71 (3.20) | 15.93 (3.78) | .41c |
| Executive function | |||
| Trail-Making Test, Part B, s | 96.48 (44.64) | 88.18 (36.10) | .48c |
| Trenerry Stroop color/word interference, No. in 120 s | 70.79 (18.80) | 79.71 (20.60) | .12c |
| Visuospatial construction, range 0-24 | |||
| Block design | 13.47 (4.07) | 13.21 (3.85) | .80c |
| R-O figure copy | 21.02 (1.87) | 20.96 (2.10) | .90c |
| Language | |||
| Fluency, No. in 60 s | |||
| Semantic | 17.48 (4.02) | 19.32 (3.49) | .09c |
| Phonemic | 43.81 (11.60) | 43.82 (11.79) | .97c |
| Boston Naming Test, range 0-30 | 27.67 (1.98) | 27.79 (1.61) | .81c |
| Attention | |||
| Trail-Making Test, Part A, s | 46.19 (13.45) | 38.18 (10.94) | .03c |
Abbreviations: CDR, Clinical Dementia Rating; CMB(+), with cerebral microbleeds; CMB(−), without CMBs; CVBI, cerebrovascular disease burden index; CVLT, California Verbal Learning Test; PiB, Pittsburgh compound B; R-O, Rey-Osterrieth; SUVR, standardized uptake value ratio; SVBI, systemic vascular disease burden index.
Unless otherwise indicated, data are given as mean (SD).
P values for PiB positivity and PiB SUVR were controlled for age and sex; SVBI and CVBI were controlled for age, sex, and global PiB SUVR.
χ2 Test.
Twenty of 21 CMB(+) participants and 33 of 34 CMB(−) participants completed PiB positron emission tomography imaging.
Twenty of 21 CMB(+) participants and 31 of 34 CMB(−) participants completed APOE genotyping.
Unpaired, 2-tailed t test.
Thirty-two of 34 CMB(−) participants completed CDR scoring.